Aromatase (CYP19A) Inhibitor Screening Kit (Fluorometric) (ab284522)
Key features and details
- Assay type: Enzyme activity (quantitative)
- Detection method: Fluorescent
- Platform: Microplate reader, Fluorescence microscope
- Sample type: Inhibitor compounds
Overview
-
Product name
Aromatase (CYP19A) Inhibitor Screening Kit (Fluorometric)
See all Aromatase kits -
Detection method
Fluorescent -
Sample type
Inhibitor compounds -
Assay type
Enzyme activity (quantitative) -
Assay duration
Multiple steps standard assay -
Product overview
The Aromatase Inhibitor Screening Kit (ab284522) (K984) enables rapid screening of drugs and other small molecules for compound-Aromatase interaction in a reliable, high-throughput fluorescence-based assay. The assay utilizes a fluorogenic substrate that is converted into a highly fluorescent metabolite detected in the visible range (Ex/Em = 488/527 nm), ensuring a high signal-to-background ratio with little interference by autofluorescence. The kit contains a complete set of reagents sufficient for performing 100 reactions in a 96-well plate format.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called K984 Aromatase (CYP19A) Inhibitor Screening Kit (Fluorometric). K984-100 is the same size as the 100 test size of ab284522.
-
Platform
Microplate reader, Fluorescence microscope
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 100 tests Aromatase Assay Buffer 1 x 100ml Aromatase Inhibitor 1 vial Aromatase Substrate 1 vial β-NADP Stock 1 vial Fluorescence Standard IV 1 x 50µl 100X NADPH Generating System II 1 vial Recombinant Human Aromatase 2 vials -
Research areas
-
Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens. -
Tissue specificity
Brain, placenta and gonads. -
Involvement in disease
Defects in CYP19A1 are a cause of aromatase excess syndrome (AEXS) [MIM:139300]; also known as familial gynecomastia. AEXS is characterized by an estrogen excess due to an increased aromatase activity.
Defects in CYP19A1 are the cause of aromatase deficiency (AROD) [MIM:107910]. AROD is a rare disease in which fetal androgens are not converted into estrogens due to placental aromatase deficiency. Thus, pregnant women exhibit a hirsutism, which spontaneously resolves after post-partum. At birth, female babies present with pseudohermaphroditism due to virilization of extern genital organs. In adult females, manifestations include delay of puberty, breast hypoplasia and primary amenorrhoea with multicystic ovaries. -
Sequence similarities
Belongs to the cytochrome P450 family. -
Cellular localization
Membrane. - Information by UniProt
-
Alternative names
- ARO
- ARO1
- Aromatase
see all
Images
-
Aromatase Substrate metabolite fluorescence standard curve. One mole of fluorescence standard corresponds to the metabolism of one mole of Aromatase Substrate.
-
Reaction kinetics of recombinant human aromatase enzyme at 37°C in the presence and absence of the indicated aromatase inhibitors. The solvent control reaction contained assay buffer with 0.2% acetonitrile.
-
Dose-response curves for various aromatase ligands of differing structural and mechanistic classes. The potent competitive inhibitor letrozole, the mechanism-based irreversible inhibitor exemestane, the phytoestrogen-like synthetic flavonoid α-naphthoflavone and the antifungal ketoconazole (a competitive inhibitor of several CYP isoforms) are plotted in the graph. For dose-response curves, percent activity was calculated for each concentration of inhibitor by comparison to activity of reactions containing no inhibitor. For each inhibitor, IC50 values were derived by 4-parameter logistic curve fitting with each point representing the mean ± SEM of at least four replicates. Assays were performed according to the kit protocol.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab284522 has not yet been referenced specifically in any publications.